Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Hypertrophic cardiomyopathy with symptoms of moderate-to-severe heart failure~* Left ventricular hypertrophy with maximum LV wall thickness ≥ 15 mm~* Left ventricular ejection fraction ≥ 50%~* Able to perform exercise testing but unable to exceed 75% of the predicted age-adjusted maximum level~Key Exclusion Criteria:~* CYP2D6 Poor Metabolizer (PM) status~* History of a known chronic liver disease~* ALT, AST, alkaline phosphatase, or LDH \> 1.5 x upper limit of normal~* Total Bilirubin \> 2.0 x upper limit of normal~* Severe LV outflow obstruction~* Asymptomatic patients or cardiomyopathy-related criteria as per protocol~* QT interval related criteria as per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perhexiline (Type: EXPERIMENTAL): Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).